维奈克拉联合阿扎胞苷治疗不适合标准化疗的新诊断急性髓系白血病疗效分析：单中心数据

OBJECTIVE: To investigate the effectiveness and safety of the VA regimen, which combines venetoclax with azacitidine in the treatment of patients with newly diagnosed acute myeloid leukemia（AML）who are not suitable candidates for conventional chemotherapy. METHODS: In the Department of Hematology at the Second Hospital of Hebei Medical University, 66 AML patients who received venetoclax and azacitidine treatment from May 2020 to March 2022 were the subject of a retrospective study. The complete remission（CR）rate, cCR rate, ORR rate, MRD negative rate, the incidence of adverse events,1-year EFS, and OS were retrospectively analyzed. Patients subgroups with varying ages, ECOG scores, primary and secondary, risk stratifications, and gene mutation were compared for differences in efficacy and survival. RESULTS: The median follow-up was 4.25（0.9–19.9）months, and the median number of treatment courses was 2（1–8）cycles. After the first cycle, the cCR rate was 78.8％, and the MRD negative rate was 51.9％. After prolonged treatment, the cCR rate was 81.8％ and MRD negative rate was 66.7％. The median EFS and OS, respectively, were13.2 and 15.3 months. Secondary AML showed inferior efficacy and prognosis. IDH1/2 or NPM1 mutation groups had a significantly higher rate of CR than the control group（P<0.05）. The CR rate and MRD negative rate of patients with rebound thrombocytosis were significantly higher than those without rebound thrombocytosis（P<0.05）. Those who had epigenetic modification mutations（DNMT3, ASXL1, TET2）were more likely to benefit from ongoing therapy. The most common grade 3 and 4 adverse reactions were neutropenia, thrombocytopenia, and anemia. CONCLUSION: In real-world patients with newly diagnosed AML who are not candidates for standard chemotherapy, the VA regimen produces rapid deep remission. Primary AML patients, rebound thrombocytosis, IDH1/2, and NPM1 gene mutations are favorable factors for treatment benefit, and adverse reactions were tolerable.